Celcuity Inc. - SIC # 8031 - OFFICES AND CLINICS OF DOCTORS OF OSTEOPATHY

Ticker Exchange SIC # Website Latest Ticker
CELC Nasdaq 8031 www.celcuity.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Celcuity Inc.

Celcuity Announces Multiple Presentations At The European Society For Medical Oncology (ESMO) Congress 2026 - Oct 5th, 2026 6:00 am
Celcuity (CELC) Dropped, So What Is Behind Its Latest Move? - Oct 2nd, 2026 7:10 pm
Celcuity Appoints David Gryska To Its Board Of Directors - Oct 2nd, 2026 6:00 am
Why Celcuity Stock Was a Winner on Wednesday - Sep 30th, 2026 3:41 pm
Celcuity Announces That REVTORPYK™ (gedatolisib) Is Now Commercially Available In The United States - Sep 30th, 2026 6:00 am
Is Celcuity (CELC) Stock a Buy? - Sep 27th, 2026 10:59 pm
Celcuity To Participate in Upcoming Investor Conferences - Sep 1st, 2026 6:30 am
Celcuity (CELC): Landmark Approval Collides With A Costly Launch - Aug 27th, 2026 2:27 pm
Celcuity Submits sNDA to FDA for REVTORPYK™ (gedatolisib) for HR+/HER2-, PIK3CA Mutant Locally Advanced or Metastatic Breast Cancer - Aug 26th, 2026 6:30 am
Celcuity (CELC) Q2 2026 Earnings Call Transcript - Aug 20th, 2026 3:14 pm
Is Celcuity (CELC) A Bargain As Losses Widen Ahead Of Its First Launch? - Aug 16th, 2026 12:11 am
How Investors May Respond To Celcuity (CELC) Winning FDA Nod For Revtopik Amid Wider Quarterly Loss - Aug 15th, 2026 10:16 pm
Celcuity Inc. Q2 2026 Earnings Call Summary - Aug 14th, 2026 6:30 am
Celcuity Inc (CELC) (Q2 2026) Earnings Call Highlights: FDA Approval and Commercial Launch ... - Aug 13th, 2026 11:02 pm
Celcuity Q2 Earnings Call Highlights - Aug 13th, 2026 5:04 pm
Celcuity Inc. Reports Release of Second Quarter 2026 Financial Results and Provides Corporate Update - Aug 13th, 2026 2:06 pm
Celcuity Schedules Release of Second Quarter 2026 Financial Results and Webcast/Conference Call - Aug 6th, 2026 6:34 am
Newly FDA-Approved REVTORPYK™ (gedatolisib) Included in the National Comprehensive Cancer Network® (NCCN®) Clinical Practice Guidelines for HR+/HER2- Locally Advanced or Metastatic Breast Cancer - Jul 30th, 2026 6:30 am
Why CELC Stock Declined 15% in a Week Despite a Major FDA Win - Jul 21st, 2026 11:27 am
Why This Biotech Stock, With Its First FDA Approval, Just Crashed By Double Digits - Jul 15th, 2026 2:16 pm